A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma-Reference-Cited by-同舟云学术

A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma

Published:2016-12 Issue:4 Volume:15 Page:337-344.e2
ISSN:1533-0028
Container-title:Clinical Colorectal Cancer
language:en
Short-container-title:Clinical Colorectal Cancer

Author:

Bowles Daniel W.,Kochenderfer Mark,Cohn Allen,Sideris Lucas,Nguyen Nghia,Cline-Burkhardt Vivian,Schnadig Ian,Choi Minsig,Nabell Lisle,Chaudhry Arvind,Ruxer Robert,Ucar Antonio,Hausman Diana,Walker Luke,Spira Alexander,Jimeno Antonio

Publisher

Elsevier BV

Subject

Gastroenterology,Oncology

Reference40 articles.

1. Comprehensive molecular characterization of human colon and rectal cancer;Nature,2012

2. PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer;Day;Clin Cancer Res,2013

3. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival;Liao;N Engl J Med,2012

4. The PTEN-PI3K pathway: of feedbacks and cross-talks;Carracedo;Oncogene,2008

5. Phosphatase protein homologue to tensin expression and phosphatidylinositol-3 phosphate kinase mutations in colorectal cancer;Frattini;Cancer Res,2005

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Treatment against Cancer Stem Cells in Colorectal Cancer;International Journal of Molecular Sciences;2024-06-05

2. PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment;International Journal of Molecular Sciences;2024-03-09

3. Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers;International Journal of Molecular Sciences;2024-02-06

4. Biomimetic Synthesis and Chemical Proteomics Reveal the Mechanism of Action and Functional Targets of Phloroglucinol Meroterpenoids;Journal of the American Chemical Society;2024-01-17

5. Validity of Meta-Analytical Data on Cutaneous Adverse Events With Phosphoinositide 3-Kinase Inhibitors;JAMA Oncology;2023-10-01